Marvell Technology Canadian Depositary Receipts (MRV)

CIBC launches additional U.S. Canadian Depositary Receipts ("CDRs")May 7, 2026 7:00 AM
PR Newswire (Canada) Expanded U.S. CDR lineup provides more opportunities for Canadian investors to access global companiesTORONTO, May 7, 2026 /CNW/ - Today CIBC announced 15 new U.S. Canadian Depositary Receipts ("CDRs"), now listed on the TSX and available for trading. Introduced to investors over four years ago, CIBC has a total of 131 CDRs, spanning six countries, available in market. CDRs make it easy to invest in many of the world's largest companies – in Canadian dollars. Offered at a fraction of the price per share of the underlying reference share, and with a built-in notional currency hedge, CDRs provide investors with affordable access to global stocks while mitigating the currency risk associated with global investing.CIBC's newest CDRs are based on well-known U.S. companies. The 15 new CDRs are listed below with corresponding TSX ticker symbols:Amphenol CDR (CAD Hedged) – APHCoreWeave CDR (CAD Hedged) – CRWVD.R. Horton CDR (CAD Hedged) – DHIFreeport-McMoRan CDR (CAD Hedged) – FCXSIntuit CDR (CAD Hedged) – INTUKLA CDR (CAD Hedged) – KLACLam Research CDR (CAD Hedged) – LRCXMarvell Technology CDR (CAD Hedged) – MRVNorthrop Grumman CDR (CAD Hedged) – NOCQuanta Services CDR (CAD Hedged) – PWRSSandisk CDR (CAD Hedged) – SNDKStryker CDR (CAD Hedged) – SYKT-Mobile CDR (CAD Hedged) – TMUSVertiv CDR (CAD Hedged) – VRTWestern Digital CDR (CAD Hedged) - WDCThese listings will add to the existing lineup of CDRs which are currently available for trading.The Prospectus Supplement for these latest Series of CDRs has been filed on SEDAR+ at www.sedarplus.ca. For more information about CDRs, please visit https://cdr.cibc.com.About CIBC  
CIBC is a leading North American financial institution with 15 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world. Ongoing news releases and more information about CIBC can be found at www.cibc.com/ca/media-centre.SOURCE CIBC Original: CIBC launches additional U.S. Canadian Depositary Receipts ("CDRs")

MRVFF: The delisting results from the acquisition of all of the issued and outstanding Common Shares of the Company by way of a plan of arrangement with Searchlight Pharma Inc. Shareholders of the Company received $1.35 per Common Share in cash.

FINRA deleted symbol:

https://otce.finra.org/otce/dailyList?viewType=Deletions

NRIFF changed to MRVFF:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Nuvo Research Inc. changed to Nuvo Pharmaceuticals Inc.

Plan of Arrangement/Name Change. Pursuant to the Arrangement, Nuvo will spin-off its drug development business into a newpublic company that will be named Crescita Therapeutics Inc. Holders of Nuvo Shares of record as of the close of business 3/3/2016 will receive (1) common share of Crescita for each Nuvo Share held. Pursuant to the Arrangement, certificates representing the Crescita Shares will be mailed commencing on or about March 4, 2016.

http://otce.finra.org/DLSymbolNameChanges

$NRIFF recent news/filings

bullish

## source: finance.yahoo.com

Tue, 10 Mar 2015 01:33:14 GMT ~ Nuvo Research® Provides Business Update

[at noodls] - Mississauga, Ontario, Canada - March 5, 2015 - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today provided a business update. ...

read full: http://www.noodls.com/view/DDD8883BA64369F0EC4BAF06607DC603C9C164E9
*********************************************************

Thu, 05 Mar 2015 12:30:00 GMT ~ Nuvo Research® Provides Business Update

[CNW Group] - Nuvo Research® Provides Business Update

read full: http://finance.yahoo.com/news/nuvo-research-provides-business-123000234.html
*********************************************************

Fri, 20 Feb 2015 17:45:00 GMT ~ NRI.TO: Cash Balance and Pending Phase 3 Trial with Pennsaid 2% Keep Nuvo Research Looking Attractive


read full: http://finance.yahoo.com/news/nri-cash-balance-pending-phase-174500855.html
*********************************************************

Thu, 19 Feb 2015 22:00:00 GMT ~ Nuvo Research® Announces 2014 Fourth Quarter & Year-End Results

[CNW Group] - Nuvo Research® Announces 2014 Fourth Quarter & Year-End Results

read full: http://finance.yahoo.com/news/nuvo-research-announces-2014-fourth-220000846.html
*********************************************************

Fri, 30 Jan 2015 16:30:00 GMT ~ NRI.TO: WF10 Fails Phase 2 Allergic Rhinitis Study


read full: http://finance.yahoo.com/news/nri-wf10-fails-phase-2-163000976.html
*********************************************************

$NRIFF charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$NRIFF company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NRIFF/company-info
Ticker: $NRIFF
OTC Market Place: OTC Pink Current
CIK code: 0001371679
Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com
Incorporated In: Canada

Business Description: Nuvo Research Inc. is a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10.

$NRIFF share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: l PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "

Nuvo Research May Be Worth The Risk Now

http://seekingalpha.com/article/2902106-nuvo-research-may-be-worth-the-risk-now

anyone listen to the CC on friday and have a breakdown that explains the price drop?

I bought in the other day. Very excited about this. Low market cap given the amount of cash they have and potential for their drug. Hope results are good

Flying along nicely, excellent volume in the last week. Cheers.

23% in last 5 days
41% in the last month
87% in the last 3 months
246% in the last 6 months

My thoughts, BUY, WF10 top line results are to be released mid-February as per Nuvo NR.

Nuvo Research currently sitting on $5 CASH per share, no debt, revenue generating drugs plus potential blockbuster drug WF10.

Again, my thoughts, BUY, this stock is on sale based on the big picture.

$NRIFF DD Notes ~ http://www.ddnotesmaker.com/NRIFF

bullish

$NRIFF recent news/filings

## source: finance.yahoo.com

Thu, 13 Nov 2014 12:30:00 GMT ~ Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel

[CNW Group] - Nuvo Research® reacquires Pennsaid® 2% rights to South America, Central America, South Africa and Israel

read full: http://finance.yahoo.com/news/nuvo-research-reacquires-pennsaid-2-123000758.html
*********************************************************

Mon, 10 Nov 2014 22:00:00 GMT ~ Nuvo Research® Announces 2014 Third Quarter Results

[CNW Group] - Nuvo Research® Announces 2014 Third Quarter Results

read full: http://finance.yahoo.com/news/nuvo-research-announces-2014-third-220000285.html
*********************************************************

Mon, 03 Nov 2014 05:01:00 GMT ~ Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals

[CNW Group] - Nuvo Research® plans Phase 3 study of Pennsaid® 2% to support international regulatory approvals

read full: http://finance.yahoo.com/news/nuvo-research-plans-phase-3-050100761.html
*********************************************************

Mon, 20 Oct 2014 17:50:00 GMT ~ NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon


read full: http://finance.yahoo.com/news/nriff-nuvo-research-sells-u-175000187.html
*********************************************************

Fri, 17 Oct 2014 12:13:58 GMT ~ Nuvo Sells Pennsaid 2% U.S. Rights for US$45M to Horizon Pharma

[at noodls] - NUVO RESEARCH® SELLS PENNSAID® 2% U.S. RIGHTS FOR US$45 MILLION TO HORIZON PHARMA -- Nuvo to Host Conference Call/Webcast at 8:30 a.m. ET -- Mississauga, Ontario, Canada - October 17, 2014 - Nuvo Research ...

read full: http://www.noodls.com/view/8A5BFE87B6AEFC4B5E1F0252FFF470E4AF6957FE
*********************************************************


$NRIFF charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$NRIFF company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NRIFF/company-info
Ticker: $NRIFF
OTC Market Place: OTC Pink Current
CIK code: 0001371679
Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com
Incorporated In: Canada

Business Description: Nuvo Research Inc. is a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10.


$NRIFF share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$NRIFF extra dd links

Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NRIFF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NRIFF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NRIFF+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/news - http://finance.yahoo.com/q/h?s=NRIFF+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NRIFF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NRIFF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NRIFF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nuvo+Research+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nuvo+Research+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nuvo+Research+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nuvoresearch.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nuvoresearch.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nuvoresearch.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NRIFF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001371679&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NRIFF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NRIFF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NRIFF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NRIFF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NRIFF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NRIFF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NRIFF+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NRIFF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NRIFF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NRIFF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NRIFF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NRIFF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NRIFF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NRIFF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NRIFF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NRIFF



$NRIFF DD Notes ~ http://www.ddnotesmaker.com/NRIFF

Then there is this from today. Market study results for WF10. Highlighted parts are mine:

http://www.prnewswire.com/news-releases/nuvo-research-completes-wf10-us-market-study-for-treatment-of-refractory-allergies-280027142.html

Nuvo Research® Completes WF10™ U.S. Market Study for Treatment of Refractory Allergies



MISSISSAUGA, ON, Oct. 22, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of a market study commissioned to investigate the U.S. opportunity for the Company's experimental immunotherapy product, WF10, as a treatment for patients with refractory allergic rhinitis. The study, performed by Psscion Lifesciences Consulting (Psscion), forecasts that WF10 could capture 10-15% of the U.S. refractory allergic rhinitis market with peak U.S. annual sales of US$0.7 billion to US$1.1 billion.

"This market study confirms the significant U.S. market opportunity for WF10 to treat refractory allergic rhinitis," said Dr. Henrich Guntermann, President of Nuvo's Europe & Immunology Group. "Our clinical and case study data suggests that WF10 is a revolutionary therapy that provides symptomatic relief from multiple airborne allergens for up to 2 years after only 5 days of treatment. We are eagerly awaiting results in Q1 2015 of our ongoing 183 patient Phase 2 allergic rhinitis clinical study that is designed to confirm the positive results achieved in our earlier 60 patient Phase 2 proof-of-concept study."

About The Psscion Study
The market study was conducted by Psscion, a U.S. based firm that provides strategic advice and market research to the pharmaceutical industry. Psscion was retained to assist Nuvo in determining the optimum strategy to maximize the value of WF10 for the treatment of refractory allergic rhinitis. In the course of the study, Psscion interviewed patients with refractory allergic rhinitis, practicing physicians specializing as allergists and immunologists and representatives from insurance companies and other payers. The additional findings in the study were:

Physicians were impressed by WF10's efficacy, long-lasting therapeutic effect, ability to treat multiple allergens with one dosing regimen and favourable safety profile as observed in the Company's completed 60 patient Phase 2 proof-of-concept study and case studies;

Patients and physicians believe that WF10 would address an unmet need in the treatment of refractory allergic rhinitis;

WF10 could be an attractive alternative to subcutaneous immunotherapy (SCIT) also known as "allergy shots" which are allergen specific and can continue for months or years causing many patients to either refuse or discontinue SCIT treatment; and

Payers rated WF10 positively and felt that WF10 was unlikely to face significant barriers to coverage.

About the Company's Ongoing WF10 Phase 2 Clinical Trial
This 16 week clinical trial is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of a regimen of five infusions of either WF10 or its main constituents (sodium chlorite and sodium chlorate) relative to saline control in allergic rhinitis patients experiencing persistence or recurrence of symptomatic episodes in spite of conventional treatment over the previous year. The trial will measure total nasal symptom score (TNSS) and other secondary endpoints. The trial is being conducted at 15 sites in Germany. It is fully enrolled with 183 patients participating. Top-line results are expected in Q1 2015. The trial is designed to confirm the results of the Company's 2010 60 patient, randomized, double-blind, placebo-controlled, single-center Phase 2 clinical study of WF10 for the treatment of allergic rhinitis which achieved statistical significance (P<0.001) for its primary endpoint (change in TNSS at week 3).

About Refractory Allergic Rhinitis
Allergic rhinitis, a highly prevalent condition characterized by nasal symptoms (runny, blocked, or itchy nose; chronic sneezing) is triggered by an inappropriate immune response to one or more allergens such as pollens, house dust mites and pet dander. Refractory allergic rhinitis patients often suffer from severe symptoms and do not respond adequately to common forms of treatment such as antihistamines and nasal corticosteroids. Most refractory allergic rhinitis patients suffer from multiple allergies.

About WF10
WF10 is a solution containing stabilized chlorite ions that focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function. WF10 is an infusion therapy currently approved only in Thailand under the name IMMUNOKINE for the treatment of post-radiation-therapy syndrome.

I'll try to resurrect this board as lots of good news has started to flood in. After the sale of Pennsaid 2% to Horizon, NRIFF now has $67M in cash. Currently more cash per share than price per share:

http://searchingwallstreet.com/nriff-nuvo-research-sells-u-s-pennsaid-rights-to-horizon/

NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon

October 20, 2014 admin Small Cap

By David Bautz, PhD & Jason Napodano, CFA

OTC:NRIFF
TSX:NRI.TO

On October 17, 2014 Nuvo Research (OTC:NRIFF) (TSX:NRI.TO) announced it completed the sale of the company’s Pennsaid 2% U.S. sales and marketing rights to Horizon Pharma (Nasdaq: HZNP) for a cash payment of $ 45 million (CAD$ 50 million). Horizon will begin commercialization of Pennsaid 2% on January 1, 2015. Nuvo continues to retain all rights to Pennsaid and Pennsaid 2% outside the U.S. and is intending to seek a marketing partner or partners for international territories.

As part of the agreement with Horizon, Nuvo will be the exclusive supplier of Pennsaid 2% to Horizon for the U.S. market. Based on the level of sales that Horizon is able to generate for Pennsaid 2%, there could be some additional upside to Nuvo through the manufacturing mark-up. In the past we have forecasted that Pennsaid 2% peak U.S. sales are roughly $ 50 million. We believe Nuvo’s manufacturing and supply agreement with Horizon equates to an additional low-single digit royalty on these sales at full scale.

This deal follows the announcement last month that Nuvo had settled the litigation with Mallinckrodt (NYSE: MNK) that included the return of all U.S. marketing and sales rights to Pennsaid and Pennsaid 2% along with a cash payment of $ 10 million USD. We believed that Nuvo would move quickly on licensing or selling the U.S. rights to Pennsaid 2% following the litigation settlement and had predicted that a deal was likely to bring in approximately $ 20-$ 30 million USD with royalties in the mid- to high-teens. Thus, our prediction was not too far from what Nuvo ended up with by selling the full rights unencumbered by royalties.

Nuvo exited the second quarter ending June 30, 2014 with $ 10.7 million CAD in the bank. We estimate burn for the third quarter 2014 was roughly $ 2.5 million CAD. Adding in the $ 10 million USD payment from Mallinckrodt and this new $ 45 million USD payment from Horizon, we now forecast that Nuvo is sitting on approximately $ 67 million CAD in cash.


We remind investors that Nuvo will be reporting top-line results from the Phase 2 clinical trial of WF10 for the treatment of allergic rhinitis in the first quarter of 2015. The large amount of cash that the company now has will aid in funding the company’s continued development of WF10, including further studies into WF10’s mechanism of action and dosing studies to determine the minimum effective dose. We provided investors a brief update on WF10 in August 2014.

Since our last Zacks Report on Nuvo on Sep. 16, 2014, the stock has risen close to 50%. Even so, we still believe the stock is undervalued as the company currently has close to $ 5.00 per share in cash. The next catalyst will be release of the Phase 2 data for WF10, with positive results likely to send the stock significantly higher. We are maintaining our ‘Buy’ rating and a $ 7.50 price target.
READ THE LATEST FULL RESEARCH REPORT HERE

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR and to view our disclaimer.

$NRIFF DD Notes ~ http://www.ddnotesmaker.com/NRIFF

bullish

$NRIFF recent news/filings

## source: finance.yahoo.com

Mon, 20 Oct 2014 17:50:00 GMT ~ NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon


read full: http://finance.yahoo.com/news/nriff-nuvo-research-sells-u-175000187.html
*********************************************************

Fri, 17 Oct 2014 12:13:58 GMT ~ Nuvo Sells Pennsaid 2% U.S. Rights for US$45M to Horizon Pharma

[at noodls] - NUVO RESEARCH® SELLS PENNSAID® 2% U.S. RIGHTS FOR US$45 MILLION TO HORIZON PHARMA -- Nuvo to Host Conference Call/Webcast at 8:30 a.m. ET -- Mississauga, Ontario, Canada - October 17, 2014 - Nuvo Research ...

read full: http://www.noodls.com/view/8A5BFE87B6AEFC4B5E1F0252FFF470E4AF6957FE
*********************************************************

Mon, 08 Sep 2014 11:30:00 GMT ~ Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals

[CNW Group] - Nuvo Research® settles litigation with Mallinckrodt Pharmaceuticals

read full: http://finance.yahoo.com/news/nuvo-research-settles-litigation-mallinckrodt-113000152.html
*********************************************************

Thu, 04 Sep 2014 11:30:00 GMT ~ Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference

[CNW Group] - Nuvo Research® to Present at Rodman & Renshaw 16th Annual Global Investment Conference

read full: http://finance.yahoo.com/news/nuvo-research-present-rodman-renshaw-113000954.html
*********************************************************

Fri, 01 Aug 2014 13:00:00 GMT ~ (T.NRI) (NRIFF): Nuvo Q2 Results In-Line, Looking Forward to WF10 Data Early 2015


read full: http://finance.yahoo.com/news/t-nri-nriff-nuvo-q2-130000440.html
*********************************************************


$NRIFF charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$NRIFF company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NRIFF/company-info
Ticker: $NRIFF
OTC Market Place: OTC Pink Current
CIK code: 0001371679
Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com
Incorporated In: Canada

Business Description: Nuvo Research Inc. is a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10.


$NRIFF share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$NRIFF extra dd links

Company name: Nuvo Research Inc.
Company website: http://www.nuvoresearch.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NRIFF+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NRIFF+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NRIFF+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/news - http://finance.yahoo.com/q/h?s=NRIFF+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NRIFF/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NRIFF+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NRIFF
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nuvo+Research+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nuvo+Research+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nuvo+Research+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nuvoresearch.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nuvoresearch.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nuvoresearch.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NRIFF
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001371679&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NRIFF&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NRIFF
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NRIFF+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NRIFF+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NRIFF
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NRIFF
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NRIFF+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NRIFF/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NRIFF+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NRIFF.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NRIFF
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NRIFF/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NRIFF/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NRIFF
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NRIFF
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NRIFF:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NRIFF
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NRIFF



$NRIFF DD Notes ~ http://www.ddnotesmaker.com/NRIFF

Missed it at open. See if there is covering

Pennsaid 2% approved! Congrats on holding.

Nice trading...holding mine willsell half at 6

Out today, $4.30. Just incredible run up. Playing similar run up, TRLPF.

Filled today 3.20. Thinke we will see 6 in February.

In from $1.66 average on reccomendation from Mike Havrilla. Would expect full retracement to $4-5 dollars. Haven't given up a share yet.

I should have gotten in this last month at 1.45 still has room to go up to pdufa

Golden Cross on Its Way

Golden cross coming.

Pdufa 2-7 pps 2.04 today will be much higher IMO in next few weeks

http://www.sbwire.com/press-releases/report-published-nuvo-research-inc-product-pipeline-review-2013-302175.htm

Nuvo Research Announces Lawsuit Against Mallinckrodt

http://www.pharmpro.com/news/2013/08/nuvo-research-announces-lawsuit-against-mallinckrodt

Nuvo Research® announces that FDA has accepted Pennsaid® 2% new drug application for review

http://online.wsj.com/article/PR-CO-20130822-905209.html

The "d" is now removed. Waiting on volume/news.

NRIFF one for 65 reverse split:

http://www.otcbb.com/asp/dailylist_detail.asp?d=05/08/2013&mkt_ctg=NON-OTCBB

65/1 split

http://www.nuvoresearch.com/investors/documents/press%20releases/2013-05-07%20%20Nuvo_To_Complete_Share_Consolidation.pdf

Q & A on CRL + Investor presentation 3-13-13

Links:

http://www.nuvoresearch.com/investors/documents/2013-03-18_Nuvo_Pennsaid2_QandA.pdf

http://www.nuvoresearch.com/investors/documents/presentations/2013-03-13%20Nuvo%20IR%20Presentation%20March_2013.pdf

I was able to sell most of my shares after CRL for @ .055. I have a GTC order at .044 hoping it gets filled. Want to have a starter before Sept. Still want my 4 bagger!

NRIFF hopes the requested study will be completed and the NDA for PENNSAID 2% will be resubmitted 3Q 2013 with an FDA decision on approval in or before 1Q 2014.

http://www.nuvoresearch.com/investors/documents/2013-03-18_Nuvo_Pennsaid2_QandA.pdf

GL longs, dumped mine at open @.06, it was worth a shot. Maybe next time.

Nice chance to scoop up some even cheaper shares over the next few months before resubmission.

I am in full agreement with you Norm, why sell for a huge loss today when you could just tuck them away for bigger returns down the road, unless one is need of capital, which I am not. Cheers!

I think I may tuck away some of my shares. This stock will not be below .10 a year from now.

Yes, unfortunately this will be delayed at least a year now, but at least it wasn't a flat out rejection. It might not be too pretty for trading today. Cheers!

NRIFF received CRL from FDA regarding PENNSAID 2%.........

NUVO RESEARCH
ANNOUNCES
FDA RESPONSE TO PENNSAID
®
2% NDA
Mississauga, Ontario,
Canada
–
March 5,2013
–
Nuvo Research Inc. (Nuvo)(TSX:NRI)

announced today that its U.S. licensing partner, Mallinckrodt
,the Pharmaceuticals Business of Covidien

(NYSE:COV),has received a Complete Response Letter (CRL)from the U.S. Food and Drug Administration (FDA)following the review of
Mallinckrodt’s New Drug Application (NDA) for diclofenac sodium topical solution,2% w/w (PENNSAID 2%).

In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%.

Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site. Pharma cokinetic studies are standard studies conducted during a drug development program to identify the total exposure or the amount of drug that reaches the blood stream after a patient receives both single and multiple doses of the product. Mallinckrodt has indicated to Nuvo
that it expects to complete the study and submit the results
to the FDA in the third calendar quarter of 2013, and that it
anticipates the FDA will provide a formal response to the filing
within 6 months thereafter. “While we are disappointed that
PENNSAID 2% will not be approved in this review cycle, we are
pleased that the FDA has outlined a clear pathway to approval that we believe can be completed in a relatively short time frame,
” said Dr. Bradley Galer, President of Nuvo’s Pain Group.“

Upon approval,PENNSAID 2% will be the first and only topical SAID in the US. featuring twice per day dosing and a
metered dose pump bottle.

PENNSAID 2% is a follow on product to original PENNSAID which is currently marketed in the U.S. by Mallinckrodt under license from Nuvo. PENNSAID 2% is a topical nonsteroidal anti-
inflammatory drug (NSAID) containing 2% diclofenac sodium compared to 1.5% for original PENNSAID. It is more
viscous than original PENNSAID, is supplied in a metered dose pump bottle and was studied in clinical trials using twice daily dosing compared to four times a day for original PENNSAID.
d.

NUVO RESEARCH
ANNOUNCES
FDA RESPONSE TO PENNSAID
®
2% NDA
Mississauga, Ontario,
Canada
–
March 5,2013
–
Nuvo Research Inc. (Nuvo)(TSX:NRI)

announced today that its U.S. licensing partner, Mallinckrodt
,the Pharmaceuticals Business of Covidien

(NYSE:COV),has received a Complete Response Letter (CRL)from the U.S. Food and Drug Administration (FDA)following the review of
Mallinckrodt’s New Drug Application (NDA) for diclofenac sodium topical solution,2% w/w (PENNSAID 2%).

In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%.

Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site. Pharma cokinetic studies are standard studies conducted during a drug development program to identify the total exposure or the amount of drug that reaches the blood stream after a patient receives both single and multiple doses of the product. Mallinckrodt has indicated to Nuvo
that it expects to complete the study and submit the results
to the FDA in the third calendar quarter of 2013, and that it
anticipates the FDA will provide a formal response to the filing
within 6 months thereafter. “While we are disappointed that
PENNSAID 2% will not be approved in this review cycle, we are
pleased that the FDA has outlined a clear pathway to approval that we believe can be completed in a relatively short time frame,
” said Dr. Bradley Galer, President of Nuvo’s Pain Group.“

Upon approval,PENNSAID 2% will be the first and only topical SAID in the US. featuring twice per day dosing and a
metered dose pump bottle.

PENNSAID 2% is a follow on product to original PENNSAID which is currently marketed in the U.S. by Mallinckrodt under license from Nuvo. PENNSAID 2% is a topical nonsteroidal anti-
inflammatory drug (NSAID) containing 2% diclofenac sodium compared to 1.5% for original PENNSAID. It is more
viscous than original PENNSAID, is supplied in a metered dose pump bottle and was studied in clinical trials using twice daily dosing compared to four times a day for original PENNSAID.
d.

was thinking the same thing. They could be waiting to release it before the open tomorrow. only a small position for me. I had to roll the dice, if they got approved this could hit 50 to $1 in a day.

News is imminent at this point. No news AH is most likely bad news!

I bought a few, and I have my popcorn ready...lets see what happens LOL!

NITE is loading up on the bid here...I haven't watched NRIFF level 2 much, so maybe that is normal.

vote on my blog
http://profitinvestin.blogspot.com/

I agree Norm and I loaded up with 100,000 shares. I do believe this will get FDA approval and by the end of this year it should be an easy double or triple. So far it seems as though NRIFF is a huge secret to wall street. One of these days it will get the streets attention and it will fly! Cheers!

Unlike big board stocks no halt for news.... news could come out mid day and see sharp spike either way...

Volume 300K+ and all buys

Okay thanks for the update!

Qtr Report is on March 20, 2013

RE: Message from the nuvoresearch.com contact page
Inbox
x


Investor Relations
10:55 AM (11 minutes ago)

to me
Results will be released after the close of the markets on March 20, 2013.

Lynn Riley
Nuvo Research Inc.
T: 905 673-4270

-----Original Message-----
From: noreply@nuvoresearch.com [mailto:noreply@nuvoresearch.com]
Sent: February-28-13 10:50 AM
To: Info
Subject: Message from the nuvoresearch.com contact page

This message was delivered from the contact page on the Nuvo Research website.

Name: ki
Email: *******@gmail.com
Telephone:
Subject: General Information

Hello,

When are you expecting Quarterly Report?

Thx